ASS1 and melanoma: Early resistance may also have accounted for the negative results with ASS1 re-expression documented in trials of ADI-PEG20 monotherapy and maintenance in patients with melanoma and thoracic cancers, respectively, and consistent with earlier preclinical data [17,49,50,51].